Eupraxia Pharmaceuticals Rated Outperform with $14 Fair Value Estimate
Eupraxia Pharmaceuticals (EPRX) received an Outperform rating from William Blair, emphasizing its lead drug EP-104GI's potential in treating eosinophilic esophagitis, with promising early trial data. The estimated peak sales potential of over $900 million suggests significant upside for investors, especially with plans to expand into additional GI indications.
View signal analysis